Your search for smoking cessation returned 67 results

At a joint meeting of the Food and Drug Administration (FDA)’s Psychopharmacologic Drugs Advisory Committee and Drug Safety Risk Management Advisory Committee, a majority vote recommended the removal of the boxed warning regarding serious neuropsychiatric adverse events from the Chantix (varenicline; Pfizer) labeling.

Varenicline did not increase the rate of cardiovascular (CV) serious adverse events, according to data from a systematic review published in the Journal of the American Heart Association.

A recent survey found that a substantial number of clinicians believe e-cigarettes can help patients reduce or stop smoking, with 37.9% stating they having recommended e-cigarettes to patients who smoke.

In a first-ever prospective study evaluating lorcaserin in reducing post-cessation weight gain in overweight and obese smokers, researchers found that lorcaserin combined with varenicline minimized weight gain and increases in waist circumference.

New trial data may alleviate some concerns regarding the smoking cessation medications varenline, bupropion and nicotine patches and the risk of neuropsych events.

According to the results of a recent review, the efficacy of nicotine replacement therapy (NRT) in achieving long-term smoking cessation varies based on NRT delivery method, dosage, and timing of initiation.

Researchers found no significant differences in rates of smoking abstinence at 26 or 52 weeks following a 12-week treatment with a nicotine patch, varenicline, or combination nicotine replacement therapy (nicotine patch + nicotine lozenge [C-NRT]), in adults trying to quit smoking.

Rather than increase the rate at which Americans successfully quit smoking, varenicline appears to have had no significant impact on the rates of smoking and the effectiveness is short-lived compared to other cessation aides.

The outpatient procedure provides noninvasive magnetic stimulation to areas of the brain known to be associated with addiction.

According to a study in The American Journal of Drug and Alcohol Abuse, psilocybin showed promise in promoting long-term smoking abstinence in the context of a structured treatment program.